<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-166554</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pyoderma gangrenosum: Classic and emerging therapies</dc:title>
<dc:description xml:lang="en">Pyoderma gangrenosum is an ulceronecrotising dermatosis that represents a challenge for any clinician, not only for its ability to mimic other dermatoses but also for its lack of response to treatment. During the past year, there have been new studies about the efficacy of standard therapies, such as cyclosporine and systemic corticosteroids. These studies showed that classic treatment was comparable, but they are insufficient as monotherapy. That being said, new emerging therapies are becoming important, as the use of corticosteroid-sparing agents, tumour necrosis factor inhibitors or even surgery. This review updates the current evidence for the treatment of pyoderma gangrenosum (AU)</dc:description>
<dc:creator>Soto Vilches, Felipe</dc:creator>
<dc:creator>Vera Kellet, Cristián</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El pioderma gangrenoso es una dermatosis ulceronecrótica que representa un desafío importante para el clínico no solo porque puede simular otras dermatosis, sino porque en general no responde a los tratamientos habituales. Durante el último año han surgido nuevos estudios acerca de la eficacia real de los tratamientos convencionales, tales como la ciclosporina y los glucocorticoides sistémicos. Estos estudios han demostrado que los tratamientos clásicos son comparables pero insuficientes como monoterapia. Han surgido nuevos tratamientos, como los agentes ahorradores de glucocorticoides, los inhibidores del factor de necrosis tumoral y la cirugía. Esta revisión es una puesta al día de la evidencia actual para el tratamiento del pioderma gangrenoso (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);149(6): 256-260, sept. 2017. ilus</dc:source>
<dc:identifier>ibc-166554</dc:identifier>
<dc:title xml:lang="es">Pioderma gangrenoso: terapias clásicas y emergentes</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d30584^s22067</dc:subject>
<dc:subject>^d38737^s22006</dc:subject>
<dc:subject>^d30164^s22073</dc:subject>
<dc:subject>^d55983^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30933^s22073</dc:subject>
<dc:subject>^d6082^s22073</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:type>article</dc:type>
<dc:date>201709</dc:date>
</metadata>
</record>
</ibecs-document>
